CDK4/6-IN-26

CDK4/6-IN-26 is a carbamate derivative that targets CDK4/CDK6. CDK4/6-IN-26 reduces CDK4/CDK6 levels, resulting in cell cycle arrest in the G0/G1 phase and in the S phase. CDK4/6-IN-26 exhibits high potency against SW480 cells (IC50 = 6.3 μM) . CDK4/6-IN-26 affects ROS levels by increasing the expression of SOD2/MnSOD. CDK4/6-IN-26 establishes several interactions with the amino acids of the CDK6 active site. CDK4/6-IN-26 can be used for the research of colorectal cancer[1].

Product Specifications

UNSPSC

12352005

Target

CDK; Reactive Oxygen Species (ROS) ; SOD

Related Pathways

Cell Cycle/DNA Damage; Immunology/Inflammation; Metabolic Enzyme/Protease; NF-κB

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Smiles

CC(C1=C(OC(C)=O)C(OC(C)=O)=C2[C@@]3(NC(OCC(C)C)=O)CCCC(C)(C)[C@]3([H])CCC2=C1)C

Molecular Formula

C28H41NO6

Molecular Weight

487.63

References & Citations

[1]Moura SPSP, et al. Synthesis and biological evaluation of novel carnosic acid derivatives with anticancer activity. RSC Adv. 2025 Oct 6;15 (44) :36861-36878.